This clinical trial is focused on studying the effectiveness and safety of a medication called obinutuzumab in patients with a kidney condition known as lupus nephritis. Lupus nephritis is a complication of lupus, an autoimmune disease where the body’s immune system mistakenly attacks its own tissues, leading to inflammation in the kidneys. The study aims to determine how well obinutuzumab works in treating this condition compared to a placebo. Obinutuzumab is administered through an intravenous infusion, which means it is given directly into a vein.

Participants in the study will receive either obinutuzumab or a placebo, and their progress will be monitored over a period of 76 weeks. The study will assess the proportion of patients who achieve a complete renal response, which means their kidney function improves significantly. Other medications involved in the study include methylprednisolone acetate, a type of steroid used to reduce inflammation, and mycophenolate mofetil, an immunosuppressant that helps control the immune system. These medications are part of the standard treatment for lupus nephritis and will be used alongside obinutuzumab or placebo.

The study will also evaluate the safety of obinutuzumab by monitoring any side effects experienced by participants. This includes checking for infusion-related reactions, changes in blood cell counts, and any signs of infection. The goal is to ensure that the treatment is not only effective but also safe for patients with lupus nephritis. Participants will have regular check-ups and tests to track their health and the effects of the treatment throughout the study period.